Sunil Hingorani-led study breaks unique tumor defense, extends survival in mice by 70 percent; initial human studies under way
March 19, 2012
| By Dean Forbes
Pancreatic cancer tumors spread quickly and are notoriously resistant to treatment, making them among the deadliest of malignancies. Their resistance to chemotherapy stems in part from a unique biological barrier the tumor builds around itself. Now scientists at the Fred Hutchinson Cancer Research Center have found a way to break through that defense, and their research represents a potential breakthrough in the treatment of pancreatic cancer.
According to data compiled by the National Cancer Data Base, survival rates among patients treated for eight types of cancer top other programs accredited by Commission on Cancer
Feb. 21, 2012
| By Dean Forbes
Five-year survival rates among patients treated by Seattle Cancer Care Alliance for eight types of cancer are higher than for patients treated at the other cancer programs accredited by the Commission on Cancer of the American College of Surgeons. The National Cancer Data Base (NCDB), which is operated jointly by the commission with the American Cancer Society, compiled the survival rate data.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.